Author: Natalya Bukreyeva; Emily K. Mantlo; Rachel A. Sattler; Cheng Huang; Slobodan Paessler; Jerry Zeldis
Title: The IMPDH inhibitor merimepodib suppresses SARS-CoV-2 replication in vitro Document date: 2020_4_9
ID: geb4esu5_2
Snippet: The effect is dose-dependent, and concentrations as low as 3.3 μM significantly reduced viral titers when the cells were pretreated prior to infection. The results of this study provide evidence that MMPD may be a viable treatment option for COVID-19. Drugs with history of being tested in human patients or used for treatment of other conditions offer the most expedient option, and several such drugs are currently being tested for efficacy agains.....
Document: The effect is dose-dependent, and concentrations as low as 3.3 μM significantly reduced viral titers when the cells were pretreated prior to infection. The results of this study provide evidence that MMPD may be a viable treatment option for COVID-19. Drugs with history of being tested in human patients or used for treatment of other conditions offer the most expedient option, and several such drugs are currently being tested for efficacy against SARS-CoV-2, including many broad-spectrum antivirals. One such antiviral, merimepodib (MMPD), has already being tested against hepatitis C in patients as well as against many emerging RNA viruses in cell culture, including Zika, Ebola, Lassa, Junin, and . CC-BY-NC-ND 4.0 International license author/funder. It is made available under a The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.04.07.028589 doi: bioRxiv preprint chikungunya viruses (1) . MMPD noncompetitively inhibits inosine-5'-monophosphate dehydrogenase (IMPDH), an enzyme responsible for de novo synthesis of guanosine nucleotides (2, 3) . In vitro, inhibition can be reversed by addition of exogenous guanosine (4).
Search related documents:
Co phrase search for related documents- broad spectrum and condition treatment: 1, 2, 3, 4, 5
- broad spectrum and IMPDH dehydrogenase: 1, 2
- broad spectrum and low concentration: 1, 2, 3, 4, 5, 6, 7, 8, 9
- broad spectrum and novo synthesis: 1, 2, 3
- broad spectrum and RNA virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- broad spectrum and SARS efficacy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
- broad spectrum and SARS efficacy test: 1, 2
- broad spectrum and significantly reduce: 1, 2, 3, 4, 5
- broad spectrum and study result: 1, 2, 3, 4
- broad spectrum and treatment option: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- broad spectrum and viable treatment option: 1
- broad spectrum and viral titer: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- broad spectrum antiviral and cell culture: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
- broad spectrum antiviral and condition treatment: 1
- broad spectrum antiviral and low concentration: 1, 2
- broad spectrum antiviral and RNA virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43
- broad spectrum antiviral and SARS efficacy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- broad spectrum antiviral and significantly reduce: 1, 2
- broad spectrum antiviral and study result: 1
Co phrase search for related documents, hyperlinks ordered by date